These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1843108)

  • 21. Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
    Adenis A; Pion JM; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
    Cancer Chemother Pharmacol; 1995; 35(6):527-8. PubMed ID: 7882462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 20th-century advances in drug therapy in oncology--Part. II.
    Dutcher JP; Novik Y; O'Boyle K; Marcoullis G; Secco C; Wiernik PH
    J Clin Pharmacol; 2000 Oct; 40(10):1079-92. PubMed ID: 11028247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.
    Hawkins MM; Wilson LM; Stovall MA; Marsden HB; Potok MH; Kingston JE; Chessells JM
    BMJ; 1992 Apr; 304(6832):951-8. PubMed ID: 1581717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
    Beck WT; Cirtain MC; Look AT; Ashmun RA
    Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of resistance to anthracyclines and vinca alkaloids.
    Danø K; Skovsgaard T; Nissen NI; Friche E; Di Marco A
    Prog Clin Biol Res; 1983; 132C():231-46. PubMed ID: 6579564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug delivery systems and combination therapy by using vinca alkaloids.
    Lee CT; Huang YW; Yang CH; Huang KS
    Curr Top Med Chem; 2015; 15(15):1491-500. PubMed ID: 25877096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity of the topoisomerase II inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Mar; 4(2):219-34. PubMed ID: 15794715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
    Danks MK; Yalowich JC; Beck WT
    Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
    Tsuruo T
    Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
    Schutz FA; Bellmunt J; Rosenberg JE; Choueiri TK
    Expert Opin Drug Saf; 2011 Jul; 10(4):645-53. PubMed ID: 21524237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
    Martino E; Casamassima G; Castiglione S; Cellupica E; Pantalone S; Papagni F; Rui M; Siciliano AM; Collina S
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2816-2826. PubMed ID: 30122223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical pharmacology and use of antineoplastic drugs.
    Greco FA; Hande KR
    J Tenn Med Assoc; 1979 Jan; 72(1):23-33. PubMed ID: 423575
    [No Abstract]   [Full Text] [Related]  

  • 35. The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags.
    Gilbar PJ; Carrington CV
    J Oncol Pharm Pract; 2006 Jun; 12(2):113-8. PubMed ID: 16984750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
    Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
    N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug therapy of malignant lymphoma].
    Ogawa M; Inagaki J
    Rinsho Hoshasen; 1985 Oct; 30(11):1317-32. PubMed ID: 2418229
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapy of solid tumors.
    Alberto P
    Aktuelle Probl Chir; 1970; 14():807-34. PubMed ID: 4147168
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel multidrug resistance in cultured leukemia and lymphoma cells detected by a monoclonal antibody to 85-kDa protein, MRK20.
    Ohtsu T; Ishida Y; Tobinai K; Minato K; Hamada H; Ohkochi E; Tsuruo T; Shimoyama M
    Jpn J Cancer Res; 1989 Nov; 80(11):1133-40. PubMed ID: 2514173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
    Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S
    Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.